AI assistant
WeRide Inc. — Regulatory Filings 2014
Apr 23, 2014
49472_rns_2014-04-23_4bfb063a-86b7-4504-a075-ea4998f46152.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
UNITED GENE HIGH-TECH GROUP LIMITED 聯合基因科技集團有限公司
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)
DELAY IN DESPATCH OF CIRCULAR RELATING TO THE
(1) MAJOR TRANSACTION;
(2) PROPOSED ISSUANCE OF CONVERTIBLE BONDS UNDER THE SPECIFIC MANDATE; AND
(3) CONTINUING CONNECTED TRANSACTION CONCERNING THE ACQUISITION OF 51% SHAREHOLDING INTEREST IN SMART ASCENT LIMITED
Reference is made to the announcements of United Gene High-Tech Group Limited (the “ Company ”) dated 18 March 2014 and 19 March 2014 (the “ Announcements ”) in relation to, among others, the Transactions (as defined in the Announcement). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless defined otherwise.
As disclosed in the Announcement, a circular (the “ Circular ”) containing, among other things, (1) further information on the Acquisition and the Acquisition Agreement and the allotment and issue of the Conversion Shares by United Gene under the Specific Mandate and the transactions contemplated hereunder pursuant to the Acquisition; (2) further information on the Continuing Connected Transaction; (3) the recommendation of the independent board committee of United Gene to the Independent Shareholders of United Gene on the Continuing Connected Transaction; (4) the advice from the independent financial advisers to the independent board committee and the Independent Shareholders of United Gene on the Continuing Connected Transaction; (5) the valuation report on the Sale Shares compiled by an independent valuer; and (6) a notice of the SGM, will be despatched to the Shareholders on or before 23 April 2014.
– 1 –
As additional time is required by the Company to prepare and finalise the contents of the Circular, the despatch of the Circular will be postponed to a date falling on or before 16 May 2014.
By Order of the Board United Gene High-Tech Group Limited Lee Nga Yan
Executive Director
Hong Kong, 23 April 2014
As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).
– 2 –